FBT up 2.4% to $108 then drifts back to 107; NASDAQ flat 4661 DOW bounced around in 425 point range. Mixed market among biotech stocks after NASDAQ and S&P sell off; momentum eases. Mid-cap immuno-oncology stocks : down AGIO, BLUE, EPZM, SGEN.; up CLVS, INCY, MDVN. Rayno Life Science Movers: Pharmacyclics (PCYC) up 16% to […]
Sequencing Remains Hot-Roche (RHHBY) Deal With Foundation Medicine (FMI) Worth $1.1B Targeted Oncology Therapy-Molecular information from pathways and biomarkers e.g. PDL-1 RNA based immunotherapy test Continuous monitoring of tumor specific information and molecular alterations All of our sequencing picks were up 1/12 on Roche equity deal to support oncology with personalized medicine development. Two other […]
Life Science Stocks Up For the Year Biotech stocks resumed their upward move near all time highs in FBT and XBI.We will review many of the stocks in our portfolios at the JPMorgan Conference next week. Motif Summary Rayno Large Cap Biopharma up 36.4% over one year Alexion (ALXN) up 5.6% Amgen (AMGN) up 3.49% […]
2015: Another Good Year Unless “Something Happens” Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as there were two major corrections in April 2014 after the Q1 “bio-bubble” […]
XLE off 4%, NASDAQ Off 1.57%, Biotech Mainly In The Green After Close: Financials and Materials also hit hard down over 2% Biotech stocks remain a safe harbor in a stormy market freaked out by the energy free-fall. Most major biotech ETFs are up FBT,XBI but the IBB was a little volatile eventually off 0.16%.KITE […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.